Memantin in der klinischen anwendung - Erfahrungen aus der praxis

Translated title of the contribution: Memantine in clinical practice - Results of an observational study

Pasquale Calabrese, Ute Essner, Hans Förstl

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


In a post-marketing surveillance study, the efficacy and tolerability of memantine (Ebixa®) was examined in patients with moderate to severe Alzheimer's disease (AD). Patients were treated with memantine 20 mg/day for six months. Memantine's efficacy was evaluated using the Mini-Mental-State Examination (MMSE), the Nurses' Observation Scale for Geriatric Patients (NOSGER) and the Explorations Module Dementia (EMD) scales, as well as by a global assessment by the physician. After six months of open label treatment with memantine, patients' cognitive function, ability to perform daily activities, and global performance have been clearly improved. Also, memantine showed an excellent tolerability profile. The results of this naturalistic study support the significant efficacy and tolerability of memantine that has been previously demonstrated in randomised, controlled clinical Alzheimer dementia trials.

Translated title of the contributionMemantine in clinical practice - Results of an observational study
Original languageGerman
Pages (from-to)64-69
Number of pages6
Issue number2
StatePublished - 2006
Externally publishedYes


Dive into the research topics of 'Memantine in clinical practice - Results of an observational study'. Together they form a unique fingerprint.

Cite this